Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More

Spark Therap (ONCE)

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from...

ONCE : 113.57 (+2.55%)
FRLN : 3.77 (-3.08%)
Hemophilia A Drug Pipeline Market Research Report 2021 Featuring Spark Therapeutics, Sigilon Therapeutics, ASC Therapeutics, Pfizer, Sanofi Genzyme, Novo Nordisk -

The "Hemophilia A - Pipeline Insight, 2021" clinical trials has been added to's offering.

ONCE : 113.57 (+2.55%)
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 -

ONCE : 113.57 (+2.55%)
FIXX : 8.64 (+0.58%)
Spark Therapeutics' SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Factor VIII (FVIII) expression was sustained in 16 of 18 participants with up to 4 years of follow-up to the administration of SPK-8011

ONCE : 113.57 (+2.55%)
Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care

- Roche will present the final analysis from the phase IIIb STASEY study, reinforcing the safety and efficacy profile of Hemlibra in a broad range of people with haemophilia A with factor VIII inhibitors1...

ONCE : 113.57 (+2.55%)
Retinal Biologics Market worth USD 34,891.44 Million by 2027, at 11.5% CAGR | Market Research Future (MRFR)

Retinal Biologics Market Overview:

ABBV : 108.31 (+1.16%)
AMGN : 213.50 (-0.05%)
REGN : 620.20 (-2.93%)
ONCE : 113.57 (+2.55%)
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform

Collaboration combines Senti Bio's leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics' investigational gene therapies targeting...

ONCE : 113.57 (+2.55%)
Gene Therapy Market Size 2021 | To Exhibit 33.6% CAGR and Hit USD 35.67 billion by 2027

The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help...

AMGN : 213.50 (-0.05%)
GILD : 70.75 (-0.62%)
GSK : 38.57 (+0.47%)
JAZZ : 135.72 (+0.27%)
SRPT : 90.09 (-0.53%)
ONCE : 113.57 (+2.55%)
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today...

ONCE : 113.57 (+2.55%)
Europe Cell and Gene Therapy Market 2021-2026: Opportunities in CMO Offering Vector-Manufacturing Services Robust Cell & Gene Therapy Pipeline Increase In Strategic Acquisitions

, /PRNewswire/ -- The report has been added to offering.

AMGN : 213.50 (-0.05%)
GILD : 70.75 (-0.62%)
ONCE : 113.57 (+2.55%)

Barchart Exclusives

Silver Looks Ugly But It Remains Above Critical Technical Support
The silver market has been downright ugly over the past weeks. Since February 2021, the price has made lower highs and lower lows, with the most recent new low for 2021 last week at just over the $22 per ounce level. I continue to buy silver on a scale-down basis, but the results have not been pretty. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar